Chairman of the Board Research and Development and Production Committee
Dr. Lundberg joined the Board of Ferring in January 2021 as a non-executive director and Chair of the Board Research and Development and Production Committee. When Dr. Lundberg joined Ferring, he had 22 years’ leadership experience with global organisations such as AstraZeneca and Eli Lilly, supervising the research and development of more than 250 drug candidates leading to 30 approved products across multiple therapeutic areas. He has also served on the boards of several biotechnology companies and on government committees in the EU and US. Dr. Lundberg has both a medical and scientific background, and before joining industry was Professor of Pharmacology at the Karolinska Institutet in Sweden
